SQZ Biotechnologies Debt to Equity Ratio 2020-2022 | SQZ

Current and historical debt to equity ratio values for SQZ Biotechnologies (SQZ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. SQZ Biotechnologies debt/equity for the three months ending March 31, 2022 was 0.00.
SQZ Biotechnologies Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.10B $0.11B 0.91
2021-12-31 $0.10B $0.12B 0.82
2021-09-30 $0.11B $0.13B 0.83
2021-06-30 $0.09B $0.15B 0.56
2021-03-31 $0.09B $0.17B 0.55
2020-12-31 $0.10B $0.13B 0.82
2020-09-30 $0.11B $0.07B 1.52
2020-06-30 $0.00B $0.00B 0.00
2020-03-31 $0.00B $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00